These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19837160)

  • 1. Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer.
    Miller WR
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):273-6. PubMed ID: 19837160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase inhibitors: cellular and molecular effects.
    Miller WR; Anderson TJ; White S; Larionov A; Murray J; Evans D; Krause A; Dixon JM
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):83-9. PubMed ID: 16002280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical issues surrounding use of aromatase inhibitors.
    Dixon JM; Renshaw L; Murray J; Macaskill EJ; Young O; Miller WR
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):97-103. PubMed ID: 16023854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
    Miller WR; Larionov A
    Breast Cancer Res; 2010; 12(4):R52. PubMed ID: 20646288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase inhibitors--gene discovery.
    Miller WR; Larionov A; Renshaw L; Anderson TJ; White S; Hampton G; Walker JR; Ho S; Krause A; Evans DB; Dixon JM
    J Steroid Biochem Mol Biol; 2007; 106(1-5):130-42. PubMed ID: 17616392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant endocrine treatment in primary breast cancer - review of literature.
    Mathew J; Asgeirsson KS; Jackson LR; Cheung KL; Robertson JF
    Breast; 2009 Dec; 18(6):339-44. PubMed ID: 19836953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant endocrine therapy for breast cancer: an overlooked option?
    Wong ZW; Ellis MJ
    Oncology (Williston Park); 2004 Apr; 18(4):411-20; discussion 421, 424, 429 passim. PubMed ID: 15134351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience.
    Miller WR; Anderson TJ; White S; Evans D; Krause A; Dixon JM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S119-23. PubMed ID: 16113088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.
    Ellis MJ; Miller WR; Tao Y; Evans DB; Chaudri Ross HA; Miki Y; Suzuki T; Sasano H
    Breast Cancer Res Treat; 2009 Jul; 116(2):371-8. PubMed ID: 18941892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
    Salmon RJ; Alran S; Malka I; de Cremoux P; Rosty C; Languille O; Campana F; ; Sigal-Zafrani B
    Am J Clin Oncol; 2006 Aug; 29(4):385-8. PubMed ID: 16891867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant endocrine therapy in breast cancer.
    Abrial C; Mouret-Reynier MA; Curé H; Feillel V; Leheurteur M; Lemery S; Le Bouëdec G; Durando X; Dauplat J; Chollet P
    Breast; 2006 Feb; 15(1):9-19. PubMed ID: 16230013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safely promoting breast-conserving surgery and preventing early relapses with an aromatase inhibitor.
    Markopoulos C
    Surg Oncol; 2008 Aug; 17(2):113-28. PubMed ID: 18178077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine therapy for early breast cancer.
    Hussain SA; Williams S; Stevens A; Rea DW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.